<DOC>
	<DOCNO>NCT01646255</DOCNO>
	<brief_summary>The primary objective study demonstrate Rotigotine transdermal patch efficacious Chinese subject advanced-stage Idiopathic Parkinson 's Disease adjuvant therapy .</brief_summary>
	<brief_title>Rotigotine Versus Placebo , A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson 's Disease Patients</brief_title>
	<detailed_description>The study include maximum 4-week Screening Period , maximum 7-week Titration Period advanced-stage Parkinson 's disease , 12-week Maintenance Period , maximum 12-day De-escalation Period advanced-stage Parkinson 's Disease 30-day Safety Follow-Up Period . The maximum study duration individual subject advanced-stage Parkinson 's disease 27 week .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>An Independent Ethics Committee ( IEC ) approve write informed consent sign date subject legal representative Subject/legal representative consider reliable capable adhere protocol ( eg , able understand complete diary ) , visit schedule , medication application accord judgment investigator Subject Idiopathic Parkinson 's Disease 3 year ' duration , define cardinal sign , Bradykinesia , plus presence least 1 follow : rest tremor , rigidity , impairment postural reflex , without know suspected cause Parkinsonism The investigator must observe subject 'on ' 'off ' state determine subject Hoehn &amp; Yahr stage 2 4 'on ' 'off ' state Subject male female age ≥30 year Screening ( Visit 1 ) Subject Mini Mental State Examination ( MMSE ) score ≥25 Screening ( Visit 1 ) Subject must stable dose Ldopa ( either shortacting sustained release [ combination Benserazide Carbidopa ] ) least 200 mg/day , administer least 2 intake , least 28 day prior Baseline ( Visit 2 ) Subject adequately control Ldopa dose ( combination Benserazide Carbidopa ) judge treat physician optimal Subject must willing able accurately complete subject diary designate day ( assistance caregiver , require ) , record period 'on without troublesome Dyskinesia ' , 'on troublesome Dyskinesia ' , 'off ' , sleep As part Screening ( pretreatment ) assessment , subject must complete diary period 6 day , 4 6 diary 'valid ' determine investigator ( see Section 9.1.1 ) It must clear investigator subject able differentiate 'on ' 'off ' state 'valid ' diary confirm subject average ≥2.5 h/day spend 'off ' state If subject receive Anticholinergic agent ( eg , Benztropine , Trihexyphenidyl , Parsitan , Procyclidine , Biperiden ) , monoamine oxidase ( MAO ) B inhibitor ( eg , Selegiline ) , and/or Nmethyldaspartate ( NMDA ) antagonist ( eg , Amantadine ) , he/she must stable dose least 28 day prior Baseline ( Visit 2 ) maintain dose duration study Subject must stable dose antiParkinsonian medication least 20 day prior complete 6 Baseline diary Subject previously participate study subject previously receive study medication investigation study Subject participate another study investigational drug do within 28 day prior Baseline Visit ( Visit 2 ) Subject history significant skin hypersensitivity adhesive transdermal preparation , recent unresolved contact dermatitis Subject lifetime history suicide attempt ( include actual attempt , interrupt attempt , aborted attempt ) , suicidal ideation past 6 month indicate positive response ( 'Yes ' ) either Question 4 Question 5 ColumbiaSuicide Severity Rating Scale ( CSSRS ) Screening ( Visit 1 ) Subject atypical Parkinson 's syndrome ( ) due drug ( eg , Metoclopramide , Flunarizine ) , Metabolic Neurogenetic Disorders ( eg , Wilson 's Disease ) , Encephalitis , Cerebrovascular Disease , Degenerative Disease ( eg , Progressive Supranuclear Palsy ) Subject history Pallidotomy , Thalamotomy , deep brain stimulation , fetal tissue transplant Subject dementia , active psychosis hallucination , severe depression Subject receive therapy Dopamine agonist either concurrently do within 28 day prior Baseline Visit ( Visit 2 ) Subject receive therapy 1 follow drug either concurrently within 28 day prior Baseline ( Visit 2 ) : Alphamethyl dopa , Metoclopramide , Reserpine , Neuroleptics ( except specific atypical neuroleptic : Olanzapine , Ziprasidone , Aripiprazole , Clozapine , quetiapine ) , MAOA inhibitor , Methylphenidate , Amphetamine Subject currently receive central nervous system ( CNS ) active therapy ( eg , sedative , hypnotic , antidepressant , anxiolytic ) , unless dose stable least 28 day prior Baseline ( Visit 2 ) likely remain stable duration study Subject current diagnosis Epilepsy , history seizure adult , history stroke , transient ischemic attack within 1 year prior Screening ( Visit 1 ) Subject clinically relevant hepatic dysfunction ( defined total bilirubin &gt; 2.0 mg/dL , Alanine Aminotransferase ( ALT ) and/or Aspartate Aminotransferase ( AST ) &gt; 2 time upper limit reference range ) Subject clinically relevant renal dysfunction ( serum creatinine &gt; 2.0 mg/dL [ &gt; 178 μmol/L ] ) Subject clinically relevant cardiac dysfunction ( cardiac disorder opinion investigator would put subject risk clinically relevant arrhythmia ) and/or myocardial infarction within last 12 month Subject QT interval correct heart rate accord Bazett 's formula ( QTcB ) ≥500 ms Screening ( Visit 1 ) Subject history symptomatic ( asymptomatic ) orthostatic hypotension , decrease systolic blood pressure ( SBP ) supine stand position ≥2 0 mmHg ≥10 mmHg DBP 1 3 minute within 28 day prior Baseline ( Visit 2 ) , SBP &lt; 105 mmHg study entry 17 . Subject evidence impulse control disorder ( ICD ) Screening ( Visit 1 ) Subject history know intolerance/hypersensitivity follow Antiemetics : Domperidone , Trimethobenzamide , Ondansetron , Tropisetron , Granisetron , Glycopyrrolate Subject history chronic alcohol drug abuse within last 5 year Subject pregnant nursing , childbearing potential ( ) surgically sterile ( ii ) use adequate birth control method ( include least double barrier method ) ( iii ) sexually abstinent ( iv ) least 2 year postmenopausal Subject clinically relevant medical condition , psychiatric condition , laboratory abnormality would , judgment investigator , interfere subject 's ability participate study</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Rotigotine</keyword>
	<keyword>Neupro phase 3</keyword>
	<keyword>Advanced-stage</keyword>
	<keyword>Idiopathic Parkinson 's Disease</keyword>
</DOC>